Does the Oncotype DX Test Create a Personalized Treatment Plan?

Oncotype DX Test: Personalizing Your Cancer Treatment

Oncotype DX TestOver the past years, treatment of breast cancer has changed significantly thanks to technology and advancements in breast cancer research. We have discovered that each breast cancer case is different. It’s important for breast cancer patients to know that there are ways of undergoing a more personalized treatment that is catered toward their type of cancer.

The Oncotype DX test allows you decipher which treatment would be the most beneficial for you.Many of times, the Oncotype DX test has determined that certain breast cancer patients wouldn’t benefit from chemotherapy.

According to Medical Director Dr. Jay Harness, “The Oncotype testing and DCIS is emerging as an important and validated tool to help us decide those patients who will benefit from adjuvant radiation therapy or not.”

But that is not all, Dr. Harness explains how the Oncotype DX test can help to personalize your breast cancer treatment.

Transcript

Jay K. Harness:  How does the Oncotype DX test lead to more personalized breast cancer treatment?  Here are some important thoughts.

Over this past decade or more, the treatment of all breast cancers has changed significantly.  This is particularly true when it comes to estrogen receptor-positive stage I and stage II breast cancers as well as changes going on in the treatment of ductal carcinoma in situ.  There is no question that in estrogen receptor-positive breast cancers, the utilization of the Oncotype DX test has become an important and invaluable tool. 

As you will recall, there are three types of recurrence scores that can be obtained, a low risk recurrence score which means that a patient does not need chemotherapy nor benefits from chemotherapy as well as the high risk score which means that the patient clearly needs chemotherapy and certainly benefits from the chemotherapy, when it comes to the intermediate risk score, other factors will go into that decision-making processes as far as the use of adjuvant chemotherapy or not. 

In estrogen receptor-positive cancers, this is in both pre and postmenopausal women and this is certainly true with those who have up to three positive lymph nodes.  It is an invaluable test leading to a personalize treatment plans and particularly the avoidance of unnecessary chemotherapy.  The same is now true for ductal carcinoma in situ.  The Oncotype testing and DCIS is emerging as an important and validated tool to help us decide those patients who will benefit from adjuvant radiation therapy or not.  If you have been diagnosed with stage I or stage II estrogen receptor-positive breast cancer or with ductal carcinoma in situ, you need to know your Oncotype recurrence score.